Shanghai, China, 19 October 2024 - Recently, the PLATINIUM™ implantable cardioverter defibrillators (ICD)，produced by MicroPort® CRM Shanghai（MicroPort Soaring CRM (Shanghai) Co., Ltd.)，an associated company of MicroPort® CRM, received approval from China’s National Medical Products Administration (NMPA). This marks the first ICD manufactured in China to gain approval for market launch and is set to be officially commercialized within the country.
The approved ICDs include two models: the dual-chamber PLATINIUM™ DR 1540 and the single-chamber PLATINIUM™ VR 1240.
ICDs are vital and widely used implantable medical devices designed to prevent sudden cardiac death. These devices offer tiered therapies, including ventricular anti-tachycardia pacing and defibrillation, to manage life-threatening ventricular arrhythmias. Recent data presented at the 15th Academic Biennial Conference of the Cardiac Electrophysiology and Pacing Branch of the Chinese Medical Association (CSPE2024) revealed that approximately 1 million people in China die from sudden cardiac death each year.
The PLATINIUM™ single-chamber ICD is expected to have a lifespan exceeding 14 years1, while the dual-chamber ICD is anticipated to last over 13 years2. This exceptional longevity significantly reduces the frequency of device replacements, thereby lowering the risk of complications associated with replacement surgeries. Additionally, the product is equipped with an advanced atrioventricular relationship-based discrimination algorithm (PARAD+™), which accurately identifies supraventricular tachycardia to avoid misdiagnosis and inappropriate treatment. Furthermore, the proprietary BTO™ algorithm enables physiological pacing for patients within the tachycardia zone.
The approval of PLATINIUM™ ICD is expected to provide a more effective option for Chinese patients at high risk of sudden cardiac death. Moving forward, MicroPort Soaring CRM will continue to expedite the localization of MRI-compatible ICDs in China while actively promoting the advancement and clinical application of ICD technology. The company remains committed to addressing the clinical needs of patients and healthcare professionals in China by providing targeted and refined solutions for cardiology treatment and management.
About MicroPort® CRM
MicroPort® CRM is a pioneering company in the field of Cardiac Rhythm Management (CRM), and a subsidiary of MicroPort Scientific Corporation (stock code: 00853.HK), with world headquarters in Clamart, near Paris, France. Through our long-standing expertise in CRM, MicroPort® CRM develops, manufactures and markets around the world cardiac pacemakers, implantable cardiac defibrillators, cardiac resynchronization systems and ECG diagnostic solutions for the management of cardiac rhythm disorders and heart failure. Our state-of-the-art products are manufactured in Clamart, France, Saluggia, Italy, and in Santo Domingo, Dominican Republic.
For more information, please refer to www.microport.com
Longevity conditions